Participants in this arm will receive MFGM-enriched full-fat dairy milk (3 servings/d) that contains MFGM at 10% phospholipid (relative to total lipid content) delivering MFGM at ~10-times that in full-fat dairy milk.

Participants in this arm will receive a matched dairy milk that instead contains soy phospholipid/lecithin.

Metabolic Syndrome

Metabolic Endotoxemia

MetS adults with metabolic endotoxemia will be enrolled to complete a 2-arm, double-blind, randomized controlled, crossover trial to test the independent benefits of MFGM. For each 2-wk arm, they will receive MFGM-enriched full-fat dairy milk (3 servings/d) or a matched dairy milk that instead contains soy phospholipid/lecithin (control). Milks have been formulated with soy lecithin or MFGM at 10% phospholipid (relative to total lipid content). This delivers MFGM at ~10-times that in full-fat dairy milk, which reflects that consumers obtain MFGM from dairy foods other than whole milk.

MFGM-enriched full-fat dairy milk

MetS adults with metabolic endotoxemia will be enrolled to complete a 2-arm, double-blind, randomized controlled, crossover trial to test the independent benefits of MFGM. For each 2-wk arm, they will receive MFGM-enriched full-fat dairy milk (3 servings/d) or a matched dairy milk that instead contains soy phospholipid/lecithin (control). Milks have been formulated with soy lecithin or MFGM at 10% phospholipid (relative to total lipid content).

Soy phospholipid/lecithin milk

The Ohio State University

Alleviation Of Metabolic Endotoxemia In Adults With Metabolic Syndrome With Milk Fat Globule Membrane

Between-treatment change in serum endotoxin (fasting) on day 14 relative to day 0

Between-treatment difference in the area under the curve of serum endotoxin (0-3 hours) on day 14

Between-treatment change in plasma glucose (fasting) on day 14 relative to day 0

Between-treatment difference in the area under the curve of plasma glucose (0-3 hours) on day 14

Between-treatment change in plasma (fasting) on day 14 relative to day 0

Between-treatment difference in the area under the curve of plasma insulin (0-3 hours) on day 14

Between-treatment change in plasma HDL-C (fasting) on day 14 relative to day 0

Between-treatment change in plasma triglyceride (fasting) on day 14 relative to day 0

Between-treatment change in plasma total cholesterol (fasting) on day 14 relative to day 0

Between-treatment change in plasma glucagon-like peptide-1 (fasting) on day 14 relative to day 0

Between-treatment difference in 24 hour urinal excretion of lactulose post-meal challenge on day 14

Between-treatment difference in 24 hour urinal excretion of sucralose post-meal challenge on day 14

Between-treatment difference in 24 hour urinal excretion of erythritol post-meal challenge on day 14

Between-treatment difference in 24 hour urinal excretion of mannitol post-meal challenge on day 14

Between-treatment difference in fecal bacterial abundance and composition on day 13

Between-treatment difference in fecal acetate on day 13

Between-treatment difference in fecal butyrate on day 13

Between-treatment difference in fecal propionate on day 13

Between-treatment change in plasma gastric inhibitory polypeptide (GIP) (fasting) on day 14 relative to day 0

Between-treatment difference in fecal calprotectin on day 13

Between-treatment difference in fecal myeloperoxidase on day 13

Between-treatment change in circulating Toll-like receptor 4 mRNA (fasting) on day 14 relative to day 0

Between-treatment change in circulating IL-6 mRNA (fasting) on day 14 relative to day 0

Between-treatment change in circulating TNFa mRNA (fasting) on day 14 relative to day 0

Between-treatment change in circulating Toll-like receptor 4 mRNA post meal challenge (0-3 h) on day 14

Between-treatment change in circulating IL-6 mRNA post meal challenge (0-3 h) on day 14

Between-treatment change in circulating TNFa mRNA post meal challenge (0-3 h) on day 14

Richard Bruno

Professor and Principal Investigator

Ohio State University

2-arm, double-blind, randomized controlled, crossover trial

Both participants and key research personnel will be blinded between MFGM-enriched full-fat dairy milk (treatment) and milk with soy phospholipid/lecithin (control).

Hypercholesterolemia

3,5-Diiodothyropropionic acid (DITPA) therapy

Johns Hopkins Bayview Medical Center

Study of 3,5-Diiodothyropropionic Acid (DITPA) in Hypercholesterolemic Patients

A Randomized, Double-Blind Placebo-Controlled Study of 3,5-diiodothyropropionic Acid (DITPA) in Combination With Standard Therapy to Attain NCEP ATP III Goal for LDL Cholesterol in Hypercholesterolemic Patients

lecithin/diarré

Alleviation Of Metabolic Endotoxemia In Adults With Metabolic Syndrome With Milk Fat Globule Membrane

Study of 3,5-Diiodothyropropionic Acid (DITPA) in Hypercholesterolemic Patients

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen